[4] This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX[5][6] Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

[10] In late 2009, the company faced a major financial setback with the termination of a multi-year collaboration agreement with Shire for its lead compound, migalastat, and two other products.

[12] In November 2013, Amicus acquired competitor Callidus Biopharma for its enzyme replacement therapy treatment for Pompe disease.

[14] Also in September 2015, Amicus announced that it would submit a new drug application (NDA) for accelerated approval of migalastat to the FDA by the end of 2015.

[19] In September 2018, Amicus announced that it had acquired Celenex, which had ten early stage gene therapies.